Alcon: Pipeline, Products, Performance, Potential

Date: February 22, 2010
Pages: 52
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A420F429467EN

Download PDF Leaflet

Alcon: Pipeline, Products, Performance, Potential
Alcon is a research and development-driven global company which develops, manufactures and markets pharmaceuticals, surgical equipment and devices, and consumer products to treat diseases and disorders of the eye. It has operations in over 75 countries and its products are sold in over 180 countries. A subsidiary of Nestlé, Alcon is a Swiss corporation.

On 7th April 2008, Novartis reached an agreement with Nestlé providing the right to acquire majority (77 per cent) ownership of Alcon in two steps. The transaction's first step, to purchase a 25 per cent stake in Alcon from Nestlé for US$143.18 per share, or US$10.4 billion, was completed in July 2008. The optional second step provides Novartis with exclusive rights to acquire the remaining 52 per cent Alcon stake held by Nestlé between 1st January 2010 and 31st July 2011, for a fixed price of US$181 per share, totalling about US$28 billion; Nestlé has the right to require Novartis to buy this stake. On 4th January 2010, Novartis and Nestlé initiated completion of the 2008 agreement.

If majority ownership is transferred from Nestlé during the second step, Novartis and Alcon will identify the best way to realise synergies from combining their complementary eye-related businesses. Potential benefits could include creating a broader portfolio of eye care products, in particular with CIBA Vision's contact lens business and Novartis medicines, such as Lucentis (ranibizumab), for severe eye diseases not addressed by Alcon's portfolio. Other opportunities include research and development activities, and an even more aggressive expansion in fast-growing regions, particularly Asia, where Novartis has longstanding operations. In addition, the relationships of Novartis with healthcare payers and strong health economics activities could contribute to Alcon's marketing programmes.

On the other side, Alcon would help limit risks within the Novartis portfolio based on its diversified payor structure, with reduced risks of price regulation, leadership in a specialty healthcare area and greater access to businesses with discretionary consumer spending.

This new strategic analysis report Alcon: Pipeline • Products • Performance • Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.


Key product analysis and forecasting
  Azarga (brinzolamide+timolol)
  Azopt (brinzolamide)
  DuoTrav (travoprost+timolol)
  Travatan (travoprost)
  Nevanac (nepafenac)
  Rimexel (rimexolone)
  TobraDex (tobramycin+dexamethasone)
  Vigamox/Vegamox (moxifloxacin)
Ocular Allergy
  Patanol/Opatanol (olopatadine)
  Ciprodex (ciprofloxacin)


A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Subsidiaries and joint ventures
Skip to top

Ask Your Question

Alcon: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: